IOL Chemicals & Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its standalone financial results for the quarter and nine months ended December 31, 2025, reporting steady growth in revenue, profitability, and margins.
Financial Highlights (Standalone)
Q3 FY26 vs Q3 FY25
Revenue from Operations: ₹580.4 crore vs ₹523.3 crore, up 10.2% YoY
EBITDA: ₹62.6 crore vs ₹50.9 crore, up 22.8% YoY
EBITDA Margin: 10.7% vs 9.7%, up 102 bps
Profit Before Tax (PBT): ₹38.8 crore vs ₹27.8 crore, up 32.3% YoY
PBT Margin: 6.6% vs 5.3%, up 134 bps
9M FY26 vs 9M FY25
Revenue from Operations: ₹1,699.6 crore vs ₹1,551.4 crore, up 9.6% YoY
EBITDA: ₹196.1 crore vs ₹157.1 crore, up 24.8% YoY
EBITDA Margin: 11.4% vs 10.0%, up 132 bps
Profit Before Tax (PBT): ₹124.8 crore vs ₹93.0 crore, up 34.2% YoY
PBT Margin: 7.3% vs 5.9%, up 134 bps
PBT and PBT margin are calculated after netting off exceptional items arising from the implementation of new labour laws.
Business & Operational Highlights
The company recognised an exceptional expense of ₹11.21 crore during the quarter following the notification of the four Labour Codes by the Government of India. The impact is regulatory and non-recurring.
Declared an Interim Dividend of ₹1 per equity share (face value ₹2) for FY26. Record date: February 17, 2026.
Approved closure of IOL Life Sciences Limited, a wholly owned subsidiary, through striking off under Section 248 of the Companies Act, 2013, as part of corporate rationalisation.
Incorporated IOL Pharmaxis UK Limited to strengthen international operations and expand global customer engagement in Pharmaceuticals and Chemicals.
Management Commentary
Mr. Vikas Gupta, Joint Managing Director, stated that Q3 FY26 was a resilient quarter marked by double-digit revenue growth, margin expansion, and a strong increase in profitability despite geopolitical uncertainties. He highlighted that the Pharmaceuticals segment remained the primary growth driver, recording 18% YoY revenue growth, with pharma’s share in total revenue rising significantly year-on-year. Growth was supported by strong traction in non-Ibuprofen APIs and a broader product mix.
The Chemicals segment also delivered improved performance with optimal capacity utilisation, efficiency gains, and sustained customer demand, leading to solid EBIT growth.
Looking ahead, the company will focus on expanding in regulated markets, strengthening its product pipeline, enhancing backward integration, and investing in R&D to sustain growth and improve competitiveness while creating long-term value for stakeholders.
